Kevin Mondet

[⚕️ D-1 | Last chance to register for the AI for Health Summit!] Don’t miss this must-attend health event, tomorrow, November 21st, 2024, co-founded by Artefact and Johnson & Johnson Innovative Medicine France. 🇫🇷 We are particularly honored to announce that the French Minister for Health and Access to Care, Geneviève Darrieussecq, will open this 7th edition with a special address. Note: The Minister's participation is subject to change in case of last-minute scheduling constraints. Join us at STATION F to hear inspiring leaders from the tech and #healthecosystem (major #pharmaceuticalgroups, institutional actors, hospitals, startups, and scale-ups), bringing together key players from both the public and private sectors. 📆 November 21st, 2024 📍 Station F, Paris ➡️ Register here to join 2,000 international participants: https://lnkd.in/ej3pUNa7 🔎 Follow the program and speaker lineup: https://lnkd.in/e-4jBwC8 At the AI for Health Summit 2024, explore exhibits from 39 exhibitors and attend over 80 sessions across 3 stages, focusing on six major themes: ⚙️ #HealthInnovation & Ecosystem 🌍 Population Health Management 📕 (Gen) #AI for Pathologies 💙 Patient Pathway and Quality of Care 🔬 (Gen) AI for #Research 🔎 #DataFoundation and Governance Come listen to over 130 top-tier speakers this Thursday! 🩺 From the #pharmaceutical and #healthcare industry: Johnson & Johnson Innovative Medicine France, Amgen, Biogen, Clariane, Novo Nordisk, Pfizer, Servier, Takeda. 🏛️ From institutions: Anap, ASPIRE, Centre Léon Bérard, EIT Health, French Ministry of Digital Health (Ministère de la Santé), CNAM, Healthcare Data Institute, Agence de l'innovation en santé, Inria, Institut Curie, IUCT-Oncopole (Institut Universitaire du Cancer de Toulouse), numeum, PariSanté Campus, Resah, Unicancer. 🚀 From the Startup and Scale-up ecosystem: Adlin Science, B Consultant, Biolevate, Bioptimus, CODOC, Deemea, Deeplife, Deep Space Biology, DrData, Doctolib, Elixir Health, Emerit Science, ErVimmune, EW2Health, GameAnalyze, GENerX Life, HelloBetter, Iktos, Implicity, Klippa, Kustoma, My S Life, Numind, Octopize, O-KIDIA, Opscidia, Praxy.ai, Pulselife, Qalita, Radiologs, Second Brain, Skezi, Skin Vision, Sparta Care, Synapse Medicine, Tandem Health, Team HART, TraceX, Trustii.io, Use & Share, Whitelab Genomics 🔧 From the Tech ecosystem: Amazon Web Services (AWS), InstaDeep, IQVIA France, Microsoft, MyData-TRUST - Data Protection & Privacy for Life Sciences, Nebius, Pure Storage, Salesforce, Sqilline Health, Theodo HealthTech (ex-Hokla), TriNetX, VIDAL. See you tomorrow!

53

1 commentaire

Opportunity

3

Only 6% of all marketed products for Multiple Sclerosis are biologics. Can you take a wild guess concerning their proportion among pipeline drug candidates for this indication? Check out our latest market and pipeline analysis for MS. #mabdesign #multipleSclerosis #biologics

7

1 commentaire

👉🏼 Chapitre 7. Applications et éclairage éthique des Intelligences Artificielles Génératives linguistiques en Médecine 🤓 Cécile Monteil 👇🏻 https://lnkd.in/e4Fnfwqw 🔍 Focus on data insights: - The integration of Generative Artificial Intelligence systems like Large Language Models (LLM) is reshaping medical practices. - Physicians are required to adapt and acquire new competencies in technology for effective utilization of Gen AI. 💡 Main outcomes and implications: - The evolving ethical framework surrounding Gen AI in medicine necessitates increased ethical vigilance. - Healthcare professionals need to balance technological advancements with preserving their medical expertise and critical thinking skills. 📚 Field significance: - The digitalization of medicine emphasizes the importance of training physicians in new technologies to maintain quality healthcare services. - Gen AI presents both risks and opportunities that require careful consideration within the healthcare sector. 🗄️: [#GenerativeAI #Healthcare #EthicalFramework #DataInsights]

3

1 commentaire

Apply before Octobre 25 to join Hack4Hope, the first hackathon dedicated to the fight against Pediatric Cancers, organized by the Paris Saclay Cancer Cluster (PSCC) and its pediatric cancers working group! It will take place on November 22, at Future4Care. 📣 Why should you apply ? - The opportunity to spend a whole morning with scientific, industry, patient families, entrepreneurship and data/IA experts to get advice and insights on your project - The opportunity to pitch your project and to give it visibility to the ecosystem - The chance to win and to get more support to accelerate your project 🔦 Who can apply ? Any innovative project, start-up that develops solutions against pediatric cancers or that could be extended to pediatric cancers : new treatments, medical device, diagnostic, solution leveraging AI ... To get more information and to apply, it's here : https://lnkd.in/dSEngFjz Imagine for Margo - Children without Cancer Foundation S LifeArc ITCC Gustave Roussy Institut Curie Servier Pharmaceuticals Owkin Sanofi Future4Care

42

2 commentaires

Dear network, 🌟 It has been a while since I last shared updates, and I'm thrilled to bring you up to speed on all that has been happening and what is ahead! 🌟 Over the past six months, I have embarked on a journey across the USA, engaging with investors, industrial partners and most importantly, users. Reflecting on my time in Silicon Valley, I have gained valuable insights into the challenges of fundraising in today's landscape. While the allure of seed-stage investment remains strong, I have observed a shift where investors increasingly seek near-series A achievements. Even as a deeptech startup, I have encountered expectations for user traction and revenue before advancing discussions. In response to this feedback, I am happy to announce that we have launched the beta-testing phase of our Orusight platform across the USA, collaborating closely with optometrists and patients to iterate and enhance our service based on their invaluable feedback. 🚀 Furthermore, I am proud to announce that RetiNov has evolved into a multinational entity, following the incorporation of our US branch. 🇺🇸 Also, I would like to extend my gratitude to Bpifrance and Les Deeptech 🚀 for featuring #Retinov in the insightful article below, which encapsulates our journey and our mission to promote healthy aging by providing healthcare professionals and their patients with predictive, actionable, and targeted solutions. Last but not least, starting next month, I commit to sharing regular updates on Retinov's progress via email every first day of the month! If you are interested, please feel free to DM me your email address, and I will ensure you are included in our mailing list. Thank you for your continued support, and here is to the exciting journey ahead! 🥂 #startup #healthcare #medicaltechnology #entrepreneurship #innovation #siliconvalley

45

9 commentaires

𝗛𝗮𝗰𝗸𝟰𝗛𝗼𝗽𝗲: 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝗳𝗼𝗿 𝗖𝗵𝗶𝗹𝗱𝗿𝗲𝗻 𝘄𝗶𝘁𝗵 𝗖𝗮𝗻𝗰𝗲𝗿 ✨   On November 22nd, the Paris Saclay Cancer Cluster (PSCC) and its Childhood Cancer Working Group, Imagine for Margo - Children without Cancer, Foundation S, and LifeArc, hosted Hack4Hope, the first-ever hackathon dedicated to pediatric cancer innovation.   This pioneering event brought together researchers, clinicians, biotech experts, patient advocates, and startups with a common goal : to improve the diagnosis, treatment, and quality of life of young cancer patients. 🏆 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝘁𝗵𝗲 𝘄𝗶𝗻𝗻𝗲𝗿𝘀! TheraSonic (1st place) developing an innovative non-invasive ultrasound-based device to temporarily open the blood-brain barrier for brain tumor treatments DeepLife (2nd place and Public Choice Award) developing a Digital Twin technology to analyze single-cell data and other datasets to support drug discovery HEPHAISTOS-Pharma (3rd place) designing and developing a new generation of immune sensors modulators in oncology.   💙 A special mention to Vesynta, winner of the Family Prize, for their precision tool to optimize dosing of pediatric cancer medicines.   🔗 Discover the press release here : https://lnkd.in/dqzDSQhE #Hackathon #Innovation #PediatricCancer #Hack4Hope #PSCC #Healthcare #Biotechnology

41

3 commentaires

A shocking diagnosis has just been made in China: a 19-year-old young man is said to be suffering from Alzheimer's disease. This discovery calls into question our knowledge of this pathology. How can we explain the early onset of this neurodegenerative disease? What implications for medical research? -- > NOT A SURPRISE ?.. BECAUSE INFECTIONS (LYME & CO) MAY TRIGGER THESE KIND OF DISEASES (stated in studies since 2006.. and till 2024) https://lnkd.in/earXTbj3 --------------------------- Updates in Alzheimer's disease: from basic research to diagnosis and therapies Abstract Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression. In this review, we first provide an update on how the risk factors, including APOE variants, infections and inflammation, contribute to AD; how Aβ and tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration. Then we summarize the commonly used experimental models, diagnostic and prediction strategies, and advances in periphery biomarkers from high-risk populations for AD. Finally, we introduce current status of development of disease-modifying drugs, including the newly officially approved Aβ vaccines, as well as novel and promising strategies to target the abnormal pTau. Together, this paper was aimed to update AD research progress from fundamental mechanisms to the clinical diagnosis and therapies. https://lnkd.in/etyf-ZmD ----------- Un diagnostic bouleversant vient d'être posé en Chine : un jeune homme de 19 ans serait atteint de la maladie d'Alzheimer. Cette découverte remet en question nos connaissances sur cette pathologie. Comment expliquer l'apparition si précoce de cette maladie neurodégénérative ? Quelles implications pour la recherche médicale ? https://lnkd.in/eWXaGhMX

1

🌟 𝗪𝗲𝗲𝗸𝗹𝘆 𝗔𝗜 𝗨𝗽𝗱𝗮𝘁𝗲𝘀 (#13) 🌟   Welcome in the 13rd edition of the weekly AI updates, and now let’s dive into the latest news about AI on LinkedIn:   1️⃣ We start with Redha C., with a nice question: What really is analytics engineering ? 🖥️ https://lnkd.in/eCyhADBQ   2️⃣ Let’s continue with Yasmine DOUADI and the migration of Mistral AI in US while OpenAI goes on Paris: 🇫🇷 🇺🇲 https://lnkd.in/eRkFhKeX   3️⃣ Why are Novartis, J&J, and BMS biopharma patent leaders in 2024? To get the answer, let's take a look at this brilliant piece of article from Brian K. Buntz: 📔 https://lnkd.in/e6Qmcfh4   4️⃣ In LLMs, having too many weights could be cumbersome for several reasons... 😵‍💫 Then, what happens if we remove 50% of Llama ? The answer is here with Philipp Schmid: https://lnkd.in/etfMHFmQ   5️⃣ Andrés Marafioti recently announced the release of SmolVLM, a small 2B VLM that generates 17 tokens/sec on a MacBook and is 7.5 to 16 times faster than Qwen2-VL ! 🚀 https://lnkd.in/eZ3CKpsU   6️⃣ Congratulations to Enveda, an AI-driven drug discovery startup, who secured $130 million to transform drug development. 👏 Thanks to Ollie Gearing for your post. https://lnkd.in/e4k2PCs8   7️⃣ From Isomorphic Labs: Take a look at this nice video where Max Jaderberg, CEO of the company, explains how AI is saving billions of years of human research time. 💡 https://lnkd.in/eQKUWJ6V   8️⃣ And we finish with Max Jakobs and a really nice article on the state of AI in Drug Discovery, and especially where we are now. 📔 https://lnkd.in/eE3unNzB   🙏 Thank you for reading and your support, and please share if you find it insightful! Wishing you all a great day ! 🫶   #LLMs #DataAnalytics #AI #DrugDiscovery #AIweeklyUpdates

18

2 commentaires

Some great insights from Prof. Chantal Henry, about the challenges of diagnosing bipolar disorder. For our English-speaking followers, we collected the key highlights below: 💡 Delayed Diagnosis and Its Consequences - It takes an average of 8 to 10 years to make the diagnosis of bipolar disorder. - Around 60% of patients will begin their illness with one or more depressions, and for them the symptoms of exaltation are extremely moderate or in any case these symptoms are not perceived as pathological by the patients and so they will not report them to the doctor. - These patients will only seek care during the depressive phases, making it complicated for the doctor to make a diagnosis of bipolar disorder. 💡 The delayed diagnosis of bipolar disorder can have grave consequences: - The first risk is suicide, as 15% of untreated bipolar patients commit suicide. - The delay in diagnosis also means that associated disorders can develop, such as addiction, anxiety, and professional/social disintegration due to work stoppages, hospitalizations, and episodes that prevent the patient from functioning. 💡 A Major Innovation: Biological Blood Test - Until now, there has been no test of this type in psychiatry. - Having a biological blood test is a major innovation that can help improve the diagnosis of bipolar disorder. Prof. Henry is the scientific director of the Pierre Daniker foundation and a psychiatrist at GHU Paris psychiatrie & neurosciences, partner in the EDIT-B Consortium. #EuropeanMentalHealthWeek #BipolarDisorder #PrecisionPsychiatry SYNLAB Italia SYNLAB International Hospital Clínic de Barcelona Fundació de Recerca Sant Joan de Déu Fundació Clínic per a la Recerca Biomèdica Parc Sanitari Sant Joan de Deu Capital Region of Denmark ProductLife Group EIT Health EIT Health France EIT Health InnoStars EIT Health Spain Azapharm

17

3 commentaires

Thanks Albert Derasse and Laetitia Parmentier for the renewed opportunity you gave me to present a module of the ICHEC data science certificate. We focused on 2 main topics: 1) What are the key data science principles applied to clinical challenges? 2) What are the key benefits and the key challenges of Generative AI applied to clinical research and clinical anamnesis? We ended up with great debate on efficiency of GenAI/LLM models vs safety of GenAI/LLM applied to real life clinical questions. #ClinicalResearch #GenAI #LLM #FAIR #Ethics #Efficiency

5

📣 [#Supporter2024 MEDigIT] 🧠 Created in 2012 by the Institut du Cerveau – Paris Brain Institute, iPEPS The Healthtech Hub is the first innovation accelerator dedicated to neuroscience in France. iPEPS helps bring innovations to patients by accelerating the development of Biotech, MedTech, or digital startups in the field of neurology, thereby facilitating market access for innovative products. 🔊 "iPEPS is determined to become a major player in the field of neurology innovation. Our mission is to fast-track the growth of startups that are revolutionizing neurological care and pushing the frontiers of what’s achievable. We are dedicated to ensuring that groundbreaking innovations reach the patients who need them most. By providing comprehensive support and resources, we aim to transform cutting-edge research into practical solutions that improve lives and advance the future of neurology." 🔧 Keywords of iPEPS The Healthtech Hub: #Innovative - #Pioneering -#Impactful 📤 If you wish to join them as a partner MEDigIT Event, contact: Célestine Fillon - Yingjie WENG

11

1 commentaire

🔊 [#Supporter2024 MedFIT] 🧠 Created in 2012 by the Institut du Cerveau – Paris Brain Institute, iPEPS The Healthtech Hub is the first innovation accelerator dedicated to neuroscience in France. iPEPS helps bring innovations to patients by accelerating the development of Biotech, MedTech, or digital startups in the field of neurology, thereby facilitating market access for innovative products. 📢 "iPEPS is determined to become a major player in the field of neurology innovation. Our mission is to fast-track the growth of startups that are revolutionizing neurological care and pushing the frontiers of what’s achievable. We are dedicated to ensuring that groundbreaking innovations reach the patients who need them most. By providing comprehensive support and resources, we aim to transform cutting-edge research into practical solutions that improve lives and advance the future of neurology." 🛠️ Keywords of iPEPS The Healthtech Hub: #Innovative - #Pioneering -#Impactful 📤 If you wish to join them as a partner MedFIT Event, contact: Célestine Fillon - Yingjie WENG

14

Our healthcare system is sick. It is overwhelmed by complexity in data, workflows, decision-making processes, and more. We could make a difference right now by investing a fraction of the millions we currently waste. By deploying algorithms that can tackle complexity better than any expert Homo Sapiens can, starting with what kills and costs the most. Instead, we spend years debating how to digitalize and standardize data based on practices that will be outdated by the time it’s done, we focus on algorithmic research that attracts grants rather than solving hospital needs, we let large media outlets spread fear about algorithms based on Tesla crashes and LLM failures, and we ask our fellow citizens to vote on the consequences of all this instead of the root causes. I am deeply grateful to AI Swiss for facilitating open discussions about the pain points faced by patients and healthcare professionals, and to domo.health and the data science at CHUV | Lausanne university hospital to give me the opportunity to contribute to solving some of the most pressing issues. Let's redefine AI together as Algorithmic Impact (instead of Apple Intelligence). In the meantime, check out this recent discussion around AI in healthcare with the impactful Lara Gervaise of Virtuosis AI: https://lnkd.in/dp54MYrA #Healthcare #AI #AISwiss #ComplexityKills #ComplexityCosts #AIasAlgorithmicImpact

29

1 commentaire